AI-Powered News Analysis•Compare coverage across the political spectrum
GoodPointsNews
Admin
Back to Dashboard
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial - Reuters

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial - Reuters

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial Reuters

July 10, 2026 at 01:46 PM Original source
1 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
1 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

Locations

China

Tags

cancer drug china clinical trial GSK Hansoh survival goal

All Coverage

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial - Reuters
Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNUXlQTnc4VFk4Uk1DZ194V2xNcEhDVkF4aDNmRXhtbnBaZVJ2TFpjSFRSUmF2Skh6R3FVZGNpWUVUckQxdDB3a1lOdVlPNk45REYzRzBLdk5sSnM3X3owa0EtN0k3VWVTODRkQ3JfVzFDOHNhNm5DWXF3Vm5rX0lJNVN5YVV6a1dLX3JNVFprZnZTMDJIOGlJV0hab21VLWxycDR6ZFNFV1E2cHR1REtkckVVd0szMFNMY25fN0w0YnpiV0NpdGdBbW1TSE90V0xxYko1eTZ4TQ?oc=5" target="_blank">GSK, Hansoh's targeted cancer drug hits main survival goal in China trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

100%

Similar Stories

Related coverage based on topic and tags

US FDA advisers endorse Grail cancer test's benefits in key vote - Reuters

US FDA advisers endorse Grail cancer test's benefits in key vote Reuters

September 23, 2026 at 11:03 PM

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion Reuters

September 24, 2026 at 04:55 AM

Merck's drug for diabetes-related eye disease meets trial goal - Reuters

Merck's drug for diabetes-related eye disease meets trial goal Reuters

September 24, 2026 at 02:52 PM

Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial - Reuters

Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial Reuters

September 22, 2026 at 11:25 AM

New hope for breast cancer patients as life-extending drug now on NHS in England

Enhertu, which can give patients an extra seven months to live on average, has been prescribed in Scotland for more than two years and is available.

September 16, 2026 at 11:50 PM

US FDA approves AbbVie's drug for Parkinson's disease - reuters.com

US FDA approves AbbVie's drug for Parkinson's disease reuters.com

September 25, 2026 at 10:57 PM